Novartis | NOVN - Net Income


Novartis reported $3.26B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Alcon AG USD 189M 28M Mar/2026
Almirall EUR 19.58M 7M Dec/2025
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Autolus Therapeutics Ltd USD -71.6M 18.73M Mar/2026
Bayer EUR 219M 2.54B Jun/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Fresenius EUR 382M 53M Jun/2026
Fresenius Medical Care EUR 218.38M 100.38M Jun/2026
Genmab DKK 303M 250M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
GRIFOLS EUR 154M 81M Jun/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
J&J USD 5.53B 299M Jun/2026
Lakefront Biotherapeutics EUR 2.11M 12.38M Jun/2026
Lonza CHF 426M 119M Jun/2025
Merck EUR 490M 169M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Novartis USD 3.26B 108M Jun/2026
Novartis USD 3.16B 747M Mar/2026
Novo Nordisk DKK 20.99B 5.9B Jun/2026
Orion EUR 140.2M 49.8M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Philips EUR 384M 233M Jun/2026
Recordati EUR 116.61M 36.45M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
UCB EUR 1.08B 608M Dec/2025